Stoke Therapeutics Inc. (STOK) News

Stoke Therapeutics Inc. (STOK): $21.16

4.37 (+26.03%)

POWR Rating

Component Grades













Add STOK to Watchlist
Sign Up

Industry: Biotech


of 403

in industry

Filter STOK News Items

STOK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

STOK News Highlights

  • For STOK, its 30 day story count is now at 3.
  • Over the past 10 days, the trend for STOK's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • RNA are the most mentioned tickers in articles about STOK.

Latest STOK News From Around the Web

Below are the latest news stories about Stoke Therapeutics Inc that investors may wish to consider to help them evaluate STOK as an investment opportunity.

Wall Street Analysts See a 192% Upside in Stoke Therapeutics, Inc. (STOK): Can the Stock Really Move This High?

The consensus price target hints at a 192.2% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | February 10, 2022

Stoke Therapeutics initiated Buy at Jefferies on potential of RNA therapy platform

Stoke Therapeutics <> is trading higher after Jefferies launched its coverage with a Buy recommendation noting the prospects of its proprietary ribonucleic acid ((RNA))

Seeking Alpha | January 31, 2022

Stoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.

Yahoo | January 13, 2022

Analysts’ Top Healthcare Picks: Exact Sciences (EXAS), BioAtla (BCAB)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exact Sciences (EXAS – Research Report), BioAtla (BCAB – Research Report) and Stoke Therapeutics (STOK – Research Report) with bullish sentiments. Exact Sciences (EXAS) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Exact Sciences, with a price target of $120.00. The company's shares closed last Tuesday at $76.19, close to its 52-week low of $73.41. According to TipRanks.

Christine Brown on TipRanks | January 11, 2022

Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies

Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.

Yahoo | January 11, 2022

Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders

Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) and Stoke Therapeutics Inc (NASDAQ: STOK ) will team up on the treatments in rare genetic neurodevelopmental diseases of the CNS. The recently discovered SYNGAP1 syndrome will be first, followed by Rett syndrome (MECP2) and an undisclosed target the biotechs say is of mutual interest. “Combining Stoke’s capabilities with Acadia’s extensive expertise in … Full story available on

Benzinga | January 10, 2022

RNA startup inks deal worth up to $967M

Bedford RNA firm Stoke Therapeutics Inc. has signed a collaboration agreement potentially worth nearly $1 billion with San Diego-based Acadia Pharmaceuticals Inc.

Yahoo | January 10, 2022

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

SAN DIEGO & BEDFORD, Mass., January 10, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Stoke Therapeutics, Inc. (Nasdaq: STOK) announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS). The collaboration includes SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mu

Yahoo | January 10, 2022

Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass., January 04, 2022--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET.

Yahoo | January 4, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6889 seconds.